Latest Conference Articles

September 9th 2015, 3:03pm

World Conference on Lung Cancer

Coexisting driver mutations in EGFR-mutant non–small cell lung cancer could potentially contribute to primary resistance to EGFR-targeted therapy.

September 9th 2015, 2:41pm

World Conference on Lung Cancer

The addition of cetuximab (Erbitux) to chemotherapy reduced the risk of death by 44% for patients with advanced squamous non–small cell lung cancer whose tumors test positive for EGFR gene amplification.

September 9th 2015, 2:36pm

World Conference on Lung Cancer

The addition of bevacizumab (Avastin) to adjuvant chemotherapy did not improve overall survival in patients with surgically resected early-stage non–small cell lung cancer.

September 9th 2015, 2:11pm

World Conference on Lung Cancer

Survival for patients with metastatic squamous non–small cell lung cancer whose tumors were positive for EGFR copy number as determined by FISH analysis tended to be better when the EGFR antibody necitumumab was added to their conventional chemotherapy.

September 9th 2015, 11:44am

World Conference on Lung Cancer

Continued treatment with gefitinib beyond progression exhibited a trend toward better outcomes in patients with T790M-negative non­–small cell lung cancer.

September 9th 2015, 8:41am

World Conference on Lung Cancer

Joshua M. Bauml, MD, assistant professor, University of Pennsylvania, discusses a novel IT platform designed to enhance lung cancer clinical trial enrollment.

September 9th 2015, 8:03am

World Conference on Lung Cancer

Lorraine Pelosof, MD, PhD, from The University of Texas Southwestern Medical Center, discusses a study looking at the incidence of never smokers diagnosed with non-small cell lung cancer (NSCLC).

September 9th 2015, 5:39am

World Conference on Lung Cancer

Pasi A. Jänne, MD, PhD, director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, discusses biomarker results from the AURA study of AZD9291.

September 9th 2015, 5:35am

World Conference on Lung Cancer

Barbara J. Gitlitz, MD, from the University of Southern California, discusses results and key takeaways from The Genomics of Young Lung Cancer Study.

September 8th 2015, 4:18pm

World Conference on Lung Cancer

A chemotherapy-free regimen of nivolumab and ipilimumab demonstrated activity as a first-line therapy for patients with advanced non–small cell lung cancer.

September 8th 2015, 3:40pm

World Conference on Lung Cancer

Treatment with the PD-1 inhibitor nivolumab demonstrated a 32% reduction in the risk of death compared with docetaxel for patients with previously treated squamous non–small cell lung cancer.

September 8th 2015, 3:28pm

World Conference on Lung Cancer

Most patients younger than age 40 with lung cancer had tumors with mutations that can be targeted with existing therapies.

September 8th 2015, 12:21pm

World Conference on Lung Cancer

Adding bevacizumab (Avastin) to a standard chemotherapy doublet reduced the risk of death by 24% and disease progression by 39% in patients with malignant pleural mesothelioma.

September 7th 2015, 3:58pm

World Conference on Lung Cancer

Ramaswamy Govindan, MD, medical oncologist, Washington University School of Medicine in St. Louis, discusses a talk given at the 16th World Conference on Lung Cancer.

September 7th 2015, 3:05pm

World Conference on Lung Cancer

Patients with newly diagnosed metastatic non-small lung cancer had double the expected response when the PD-L1 inhibitor atezolizumab was added to chemotherapy.

September 7th 2015, 1:42pm

World Conference on Lung Cancer

Everett E. Vokes, MD, chair, Department of Medicine, investigator of head and neck and lung cancer, University of Chicago, discusses a plenary session that covered prevention and screening at the 16th World Conference on Lung Cancer.

September 7th 2015, 1:13pm

World Conference on Lung Cancer

Overregulation of new drug development has driven up the cost of care and resulted in significant loss of human life by delaying the approval of effective medications.

July 16th 2015, 2:09pm

ESMO Gastrointestinal Cancers Congress

Axel Grothey, MD, department of Oncology, Mayo Clinic, Rochester, MN, discusses the differences between the CORRECT and CONCUR trials, which both looked at regorafenib for previously treated metastatic colorectal cancer (mCRC).

July 15th 2015, 10:43am

ESMO Gastrointestinal Cancers Congress

Yung-Jue Bang, MD, PhD, discusses pembrolizumab for the treatment of advanced gastric cancer. Pembrolizumab was investigated as part of the KEYNOTE-012 study, which looked at the checkpoint inhibitor across several solid tumors.

July 7th 2015, 1:03pm

ESMO Gastrointestinal Cancers Congress

Michael Manns, MD, the Director of the Department of Gastroenterology, Hepatology and Endocrinology at the Medical School of Hannover in Germany, explains risk factors for hepatitis C-related hepatocellular carcinoma.